drug_type
RELEVANT_DRUG
intervention_type
Radioimmunotherapy (radioligand/antibody conjugate)
drug_description
PSMA-targeted radioimmunotherapy: a humanized anti-PSMA monoclonal antibody (rosopatamab) chelated via tetraxetan (DOTA) to beta-emitting lutetium-177 to deliver targeted radiation to PSMA-expressing prostate cancer cells, causing DNA double-strand breaks and cell death.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Lutetium-177
drug_category
RADIOIMMUNOCONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized anti-PSMA monoclonal antibody (rosopatamab) chelated via tetraxetan (DOTA) to beta-emitting lutetium-177 binds PSMA on prostate cancer cells and delivers targeted ionizing radiation, inducing DNA double-strand breaks and tumor cell death.
drug_name
177Lu-TLX591 (lutetium-177 rosopatamab tetraxetan)
nct_id_drug_ref
NCT06520345